Cargando…

Neoadjuvant PD-1 blockade: a promising nonoperative strategy for mismatch repair–deficient, locally advanced rectal cancer

Detalles Bibliográficos
Autores principales:	Mi, Mi, Ye, Chenyang, Yuan, Ying
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Research Highlight
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9551080/ https://www.ncbi.nlm.nih.gov/pubmed/36216819 http://dx.doi.org/10.1038/s41392-022-01216-3

Ejemplares similares

PD-1 blockade in neoadjuvant setting of DNA mismatch repair-deficient/microsatellite instability-high colorectal cancer
por: Liu, Ding-Xin, et al.
Publicado: (2020)

Mismatch repair deficiency in metastatic prostate cancer: Response to PD-1 blockade and standard therapies
por: Graham, Laura S., et al.
Publicado: (2020)

Enhancing prime editing via inhibition of mismatch repair pathway
por: Jiang, Lurong, et al.
Publicado: (2022)

Structural insights into Cas9 mismatch: promising for development of high-fidelity Cas9 variants
por: Tang, Honghai, et al.
Publicado: (2022)

Deletion of the RNA-editing enzyme ADAR1A: new strategy to potentiate responses to PD-1 immune checkpoint blockade
por: Wang, Manni, et al.
Publicado: (2019)

Mismatch repair deficiency in rectal cancer: an evolving scenario
por: Longo, Federico, et al.
Publicado: (2022)

Fecal microbiota transplantation: can it circumvent resistance to PD-1 blockade in melanoma?
por: Derosa, Lisa, et al.
Publicado: (2021)

Tumor cells versus host immune cells: whose PD-L1 contributes to PD-1/PD-L1 blockade mediated cancer immunotherapy?
por: Tang, Fei, et al.
Publicado: (2018)

In search for novel strategies towards neuroprotection and neuroregeneration: is PPARα a promising therapeutic target?
por: Moreno, Sandra, et al.
Publicado: (2015)

The efficiency of neoadjuvant chemotherapy in colon cancer with mismatch repair deficiency
por: Yunlong, Wu, et al.
Publicado: (2022)

The prognostic and predictive value of mismatch repair status in patients with locally advanced rectal cancer following neoadjuvant therapy
por: Wu, Zehua, et al.
Publicado: (2022)

Pediatric Rectal Adenocarcinoma With Mismatch Repair Deficiency Responds to Immunotherapy
por: Qureshi, Naveen, et al.
Publicado: (2023)

Clonal replacement of novel T cells: a new phenomenon in the tumor microenvironment following PD-1 blockade
por: Li, Xue, et al.
Publicado: (2019)

Survival outcomes analysis according to mismatch repair status in locally advanced rectal cancer patients treated with neoadjuvant chemoradiotherapy
por: Chen, Lin, et al.
Publicado: (2022)

Controversies and management of deficient mismatch repair gastrointestinal cancers in the neoadjuvant setting
por: Boutin, Mélina, et al.
Publicado: (2023)

Association of mismatch repair status with survival and response to neoadjuvant chemo(radio)therapy in rectal cancer
por: Ye, Shu-Biao, et al.
Publicado: (2020)

A Patient With Locally Advanced Mismatch-Repair-Deficient Pancreatic Ductal Adenocarcinoma Successfully Treated With Neoadjuvant Immunotherapy
por: Cox, Ronald E, et al.
Publicado: (2021)

The degree of microsatellite instability predicts response to PD-1 blockade immunotherapy in mismatch repair-deficient/microsatellite instability-high colorectal cancers
por: Wang, Qiao-Xuan, et al.
Publicado: (2021)

Dickkopf 1 impairs the tumor response to PD-1 blockade by inactivating CD8+ T cells in deficient mismatch repair colorectal cancer
por: Sui, Qiaoqi, et al.
Publicado: (2021)

Targeting PCSK9: a promising adjuvant strategy in cancer immunotherapy
por: Almeida, Catarina R., et al.
Publicado: (2021)

CRISPR-mediated RNA base editing: a promising strategy to rescue deafness
por: Liu, Wenyi, et al.
Publicado: (2023)

Targeting menin: a promising therapeutic strategy for susceptible acute leukemia subtypes
por: Di Fazio, Pietro
Publicado: (2023)

Correction: Dickkopf 1 impairs the tumor response to PD-1 blockade by inactivating CD8+ T cells in deficient mismatch repair colorectal cancer
Publicado: (2021)

The body's integrated repair kit: Studying mesenchymal stem cells for better ligament repair
por: Häfner, Sophia Julia
Publicado: (2019)

Dietary reprogram of macrophages for cell competition: a promising strategy for malignant cancer control
por: Chen, Jian, et al.
Publicado: (2023)

Nonoperative versus operative approach according to the response to neoadjuvant chemoradiotherapy for rectal cancer: A prospective cohort study
por: Bulens, Philippe P., et al.
Publicado: (2022)

Mismatch repair–deficient prostate cancer with parenchymal brain metastases treated with immune checkpoint blockade
por: Sena, Laura A., et al.
Publicado: (2021)

CDK4/6 blockade provides an alternative approach for treatment of mismatch-repair deficient tumors
por: Salewski, Inken, et al.
Publicado: (2022)

Targeting chemokines/chemokine receptors: a promising strategy for enhancing the immunotherapy of pancreatic ductal adenocarcinoma
por: Gong, Ruining, et al.
Publicado: (2020)

Mechanism of action of PD‐1 receptor/ligand targeted cancer immunotherapy [Image: see text]
por: Borst, Jannie, et al.
Publicado: (2021)

Targeting H3K36 methyltransferases NSDs: a promising strategy for tumor targeted therapy
por: Peng, Xuerun, et al.
Publicado: (2021)

A promising strategy against SARS-CoV-2: pyrimidine inhibitors synergize with nucleoside analogues
por: Min, Long, et al.
Publicado: (2022)

Developments in Checkpoint Inhibitor Therapy for the Management of Deficient Mismatch Repair (dMMR) Rectal Cancer
por: Su, Alan, et al.
Publicado: (2023)

Neoadjuvant PD-1 blockade combined with chemotherapy is not superior to neoadjuvant chemotherapy alone in resectable locally advanced esophageal carcinoma
por: Cheng, Daoan, et al.
Publicado: (2023)

Epigenetic checkpoint blockade: new booster for immunotherapy
por: Wang, Ziqiao, et al.
Publicado: (2021)

A role for complement blockade in kidney transplantation
por: Karpman, Diana, et al.
Publicado: (2022)

Cytokeratin 7 Expression and Mismatch Repair Status for Survival Prediction in Patients With Low Rectal Cancer After Neoadjuvant Therapy
por: Shi, Songli, et al.
Publicado: (2023)

Clinical significance of neoadjuvant chemotherapy for locally advanced colorectal cancer patients with deficient mismatch repair: possibly residual value in the era of immunotherapy
por: Chen, Mian, et al.
Publicado: (2023)

Genomic Determinants of De Novo Resistance to Immune Checkpoint Blockade in Mismatch Repair–Deficient Endometrial Cancer
por: Gulhan, Doga C., et al.
Publicado: (2020)

Mismatch repair deficiency predicts response to HER2 blockade in HER2-negative breast cancer
por: Punturi, Nindo B., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_767qal1q7167uh869115r6421n